SetPoint Medical announced that the FDA has approved the company’s SetPoint System, a first-in-class neuroimmune modulation innovation for treatment of moderate-to-severe rheumatoid arthritis (RA) for those who are not adequately managed by—or cannot tolerate—existing advanced RA therapies, such as biological and targeted synthetic DMARDs.
Although most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn't respond adequately to the interleukin-17 (IL-17) inhibitor ixekizumab (Taltz), enough did that it should still be considered in such cases, a Danish registry study indicated.
A cohort study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) patients from the French Vasculitis Study Group failed to show superiority of rituximab compared to conventional strategy with glucocorticoids (GS) alone or in combination with cyclophosphamide.
The annual Medscape Physician Compensation report was published and shows only modest salary gains for most specialists.
U.S. News & World Report has published its Best Hospitals for 2025, listing the best among many specialties, including rheumatology. Each year, U.S. News ranks hospitals in 15 specialties and for the 8th year in a row, Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report.
Lupus nephritis patients on long-term therapy with hydroxychloroquine showed significantly less decline in renal function, compared with patients treated otherwise, a 10-year retrospective study indicated.
A San Francisco Rheumatoid Arthritis Panel cohort survey between 1999–2011, showed numerous sociodemographic, disease, and health characteristics that influenced the initiation of treatment with biologic agents for rheumatoid arthritis (RA).
Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.
A target trial emulation study using administrative claims suggests that romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis.
Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer.
A systematic review shows that imaging can be used to detect subclinical synovitis among patients with psoriasis and may identify individuals at risk for future psoriatic arthritis.
A systematic review of anti-RNA polymerase III antibodies (ARA) in systemic sclerosis (SSc) patients finds ARA positivity in only 9% of SSc patients, but come with a higher risk of many potentially worrisome outcomes.
On June 27th, 2025, the FDA approved emapalumab for macrophage activation syndrome (MAS) in known or suspected Still’s disease (including both adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)) with inadequate response or intolerance to glucocorticoids.
A retrospective Harvard affiliates study shows that rheumatoid arthritis (RA) patients with lung disease have higher mortality, especially respiratory and infection-related mortality than those without lung disease (LD).
Women exposed to pesticides through farm work or as farmers' wives face increased risk for developing rheumatoid arthritis, a new analysis of Agricultural Health Study data indicated.
